Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast Cancer · Advanced CCNE1-amplified Solid Tumors · Metastatic Castration-resistant Prostate Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 205 (planned)
- Started
- Dec 29, 2025
- Main results expected
- May 9, 2031
- Fully finished
- May 9, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase I: Incidence and severity of dose-limiting toxicities (DLTs)
Measured over: 28 days
Phase I and phase II: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Measured over: Up to approximately 2 years
Phase I and phase II: Frequency of dose interruptions, reductions and discontinuations
Measured over: Up to approximately 2 years
Phase I and phase II: Dose intensity
Measured over: Up to approximately 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07288359 · record last updated 2026-10-29 · checked 2026-11-09 15:47 UTC